FDA Halts Clinical Trial of Celebrex
The FDA has halted a clinical trial of the Cox-2 Inhibitor Celebrex because there were more cardiovascular events in those participants taking Celebrex than among those taking a placebo. Doctors are advised to evaluate the appropriateness of prescribing Celebrex and, when possible, consider an alternative; when the drug is prescribed, the FDA recommends prescribing the lowest dose possible. [FDA]

<< Home